RANKL is mediator of bone resorption in idiopathic hypercalciuria

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 5, 2008, Pages 1446-1452

  Gomes, Samirah Abreu ^a   dos Reis, Luciene Machodo ^b   Noronha, Irene Lourdes ^b   Jorgetti, Vanda ^b   Heilberg, Ita Pfeferman ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BONE DENSITY; CASE CONTROL STUDY; CHEMISTRY; FEMALE; HUMAN; HYPERCALCIURIA; ILIAC BONE; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; OSTEOLYSIS; PATHOLOGY; UPREGULATION;

ADULT; BONE DENSITY; BONE RESORPTION; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPERCALCIURIA; ILIUM; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1ALPHA; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 53749101543     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00240108     Document Type: Article

References (50)

1. Coe FL, Evan A, Worcester E: Kidney stone disease. J Clin Invest 115: 2598-2608, 2005
2. Pak CY, Odvina CV, Pearle MS, Sakhaee K, Peterson RD, Poindexter JR, Brinkley LJ: Effect of dietary modification on urinary stone risk factors. Kidney Int 68: 2264-2273, 2005
3. Heilberg IP, Weisinger JR: Bone disease in hypercalciuria. Curr Opin Nephrol Hypertens 15: 394-402, 2006
4. Heilberg IP, Martini LA, Szejnfeld VL, Carvalho AB, Draibe SA, Ajzen H, Ramos OL, Schor N: Bone disease in calcium stone forming patients. Clin Nephrol 42: 175-182, 1994
5. Heilberg IP, Martini LA, Teixeira SH, Szejnfeld VL, Carvalho AB, Lobao R, Draibe SA: Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron 79: 430-437, 1998
6. Misael da Silva AM, dos Reis LM, Pereira RC, Futata E, Branco-Martins CT, Noronha IL, Wajchemberg BL, Jorgetti V: Bone involvement in idiopathic hypercalciuria. Clin Nephrol 57: 183-191, 2002
7. Pacifici R, Rothstein M, Rifas L, Lau KH, Baylink DJ, Avioli LV, Hruska K: Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 71: 138-145, 1990
8. Bataille P, Achard JM, Fournier A, Fournier A, Boudailliez B, Westeel PF, el Esper N, Bergot C, Jans I, Lalau JD, Petit J: Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 39: 1193-1205, 1991
9. Weisinger JR, Alonzo E, Bellorin-Font E, Blasini AM, Rodriguez MA, Paz-Martínez V, Martinis R: Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 49: 244-250, 1996
10. Ghazali A, Fuentes V, Desaint C, Bataille P, Westeel A, Brazier M, Prin L, Fournier A: Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 82: 32-38, 1997
11. Melton LJ 3rd, Crowson CS, Khosla S, Wilson DM, O'Fallon WM: Fracture risk among patients with urolithiasis: A population-based cohort study. Kidney Int 53: 459-464, 1998
12. Bordier P, Ryckewart A, Gueris J, Rasmussen H: On the pathogenesis of so-called idiopathic hypercalciuria. Am J Med 63: 398-409, 1977
13. Malluche HH, Tschoepe W, Ritz E, Meyer-Sabellek W, Massry SG: Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 50: 654-658, 1980
14. Steiniche T, Mosekilde L, Christensen MS, Melsen F: A histomorphometric determination of iliac bone remodeling in patients with recurrent renal stone formation and idiopathic hypercalciuria. APMIS 97: 309-316, 1989
15. Ghazali A, Bataille P, Solal MC, Marie A, Brazier M, Sebert JL, Prin L, Fournier A: Bone involvement in idiopathic calcium lithiasis. Nephrologie 16: 351-369, 1995
16. Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY: Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int: 71: 808-815, 2007
17. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL: IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int 63: 899-907, 2003
18. Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U, Hein G, Hüfner M: Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 18: 529-537, 2003
19. Gomes SA, Dos Reis LM, Oliveira IB, Noronha IL, Jorgetti V, Heilberg IP: Usefulness of a quick decalcification of bone sections embedded in methyl metacrylate: An improved method for immunohistochemistry. J Bone Miner Metab 26: 110-113, 2008
20. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 9: 1137-1141, 1994
21. Dos Reis LM, Batalha JR, Muñoz DR, Borelli A, Correa PH, Carvalho AB, Jorgetti V: Brazilian normal static bone histomorphometry: Effects of age, sex, and race. J Bone Miner Metab 25: 400-406, 2007
22. Melsen F, Mosekilde L: Tetracycline double-labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res 26: 99-102, 1978
23. Hestebech J, Hansen HE, Amdisen A, Olsen S: Chronic renal lesions following long treatment with lithium. Kidney Int 12: 205-213, 1977
24. Heilberg IP: Hypercalciuria. In: Encyclopedia of Endocrine Diseases, Vol. 2, edited by Martini L, San Diego, Academic Press, 2004, pp 530-536
25. Bushinsky DA: Genetic hypercalciuric stone-forming rats. Curr Opin Nephrol Hypertens 8: 479-488, 1999
26. Pacifici R: Idiopathic hypercalciuria and osteoporosis-distinct clinical manifestations of increased cytokine-induced bone resorption? J Clin Endocrinol Metab 82: 29-31, 1997
27. Raisz LG: Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115: 3318-3325, 2005
28. Mundy GR, Boyce B, Hughes D, Wright K, Bonewald L, Dallas S, Harris S, Ghosh-Choudhury N, Chen D, Dunstan C: The effects of cytokines and growth factors on osteoblastic cells. Bone 17: 71S-75S, 1995
29. Tashjian AH Jr, Voelkel EF, Lazzaro M, Singer FR, Roberts AB, Derynck R, Winkler ME, Levine L: Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc Natl Acad Sci U S A 82: 4535-4538, 1985
30. Lieb E, Miltz S, Volgel T, Hacker M, Dauner M, Shultz MB: Effects of transforming growth factor beta1 on bonelike tissue formation in three-dimensional cell culture. II: Osteoblastic differentiation. Tissue Eng 10: 1414-1425, 2004
31. Cao J, Venton L, Sakata T, Halloran BP: Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18: 270-277, 2003
32. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T: Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone 25: 517-523, 1999
33. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT: Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25: 525-534, 1999
34. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF: MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 17: 2068-2079, 2002
35. Nakamura H, Tsuji T, Hirata A, Yamamoto T: Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. J Histochem Cytochem 50: 945-953, 2002
36. Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, Tremante E, Sardella D, Bonucci E: Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol 36: 59-67, 2005
37. Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR: Increased osteoblastic activity and expression of receptor activator of NF-kappaB ligand in nonuremic nephrotic syndrome. J Am Soc Nephrol 16: 2198-2204, 2005
38. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X: RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117: 86-92, 2002
39. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM: Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111: 821-831, 2005
40. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 15: 423: 337-342, 2003
41. Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90: 6323-6331, 2005
42. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y: Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14: 518-527, 1999
43. 3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 72: 25-32, 1982
44. Olmer M, Berland Y, Argemi B: Absence of secondary hyperparathyroidism in most patients with renal hypercalciuria. Kidney Int Suppl 16: S175-S179, 1983
45. Broadus AE, Insogna KL, Lang R, Ellison AF, Dreyer BE: Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 311: 73-80, 1984
46. Insogna KL, Broadus AE, Dreyer BE, Ellison AF, Gertner JM: Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab 61: 490-495, 1985
47. Favus MJ, Karnauskas AJ, Parks JH, Coe FL: Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 89: 4937-4943, 2004
48. Breslau NA, Preminger GM, Adams BV, Otey J, Pak CY: Use of ketoconazole to probe the pathogenic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. J Clin Endocrinol Metab 75: 1446-1452, 1992
49. Krieger NS, Stathopoulos VM, Bushinsky DA: Increased sensitivity to 1.25(OH)2D3 in bone from genetic hypercalciuric rats. Am J Physiol 271: C130-C135, 1996
50. Gonzalez EA: The role of cytokines in skeletal remodelling: Possible consequences for renal osteodystrophy. Nephrol Dial Transplant 15: 945-950, 2000